Hello there,
This year-end issue of The seqWell Scope celebrates the accomplishments we’ve made in revolutionizing single-cell RNA sequencing.
RNA-seq is a crucial tool for several areas within biological research and discovery, including drug screening pipelines and single-cell analysis. At seqWell we recognize that, in improving our ability to process large numbers of RNA samples with ease, we can accelerate the pace and scale of sequencing for these applications.
Last month, we participated in a webinar on optimizing scRNA-seq workflows. During the discussion, Curtis Knox, our director of product management, highlighted the seqWell technologies that enable high-throughput workflows for a variety of applications, including scRNA-seq. Then, Dave Rawling, PhD, one of our senior scientists and R&D team leaders, discussed the development effort he has been spearheading.
Dr. Rawling and his team are working to build the next generation of highly scalable RNA-seq assays. They are taking our plexWell™ Rapid Single Cell kit, which we built and launched last year, and combining it with the revolutionary simplicity of our new ExpressPlex™ technology, which we will launch as a standalone product in 2023. I encourage you to check out the webinar and download Dr. Rawling's poster presentation to learn more about these products. You can also request early access to begin leveraging ExpressPlex for your work.
The new year will kick off with conferences that focus on additional applications that we are continuing to push the boundaries on. If you’re planning to attend PAG in January or AGBT in February, please find us and say hello. Our team would love to discuss how our products and tools, like our transposase-based toolkit, can support your research.
On behalf of everyone here at seqWell, I wish you all the best in the year to come.
See you in 2023!
Best regards,
